What do systematic reviews say?

Oral ciprofloxacin and inhaled colistin vs inhaled tobramycin

The review found no eligible studies for this question.

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Oral ciprofloxacin and inhaled colistin vs inhaled tobramycin (TNS) plus oral ciprofloxacin

The review found no eligible studies for this question.

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists

The review found no eligible studies for this question.

• Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol

• Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 600 participants
  Moderate

Inhaled tobramycin (TNS) vs placebo

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Very low

Cycled inhaled tobramycin vs culture‐based TNS

The review found no eligible studies for this question.

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Oral ciprofloxacin and inhaled colistin vs no treatment

The review found no eligible studies for this question.

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI

The review found no eligible studies for this question.

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Short‐acting inhaled beta‐2 agonists vs placebo

It is very uncertain whether short‐acting inhaled beta‐2 agonists changes change from baseline in FVC (% predicted) compared with placebo (very low certainty).

• Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 100 participants
  Very low

Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)

• Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Low

Summary of findings ‐ Inhaled mannitol vs dornase alfa

It is very uncertain whether summary of findings ‐ Inhaled mannitol changes lung function: FVC mL (percentage change from baseline) compared with dornase alfa (very low certainty).

• Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
  MD 0.14
  231 participants
  Very low

Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)

• Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1261 participants
  Low

Short‐acting inhaled muscarinic antagonists vs placebo

The review found no eligible studies for this question.

• Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Inhaled corticosteroids vs placebo

• Inhaled corticosteroids for cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 250 participants
  Low

Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 32 participants
  Very low

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

It is very uncertain whether summary of findings ‐ Inhaled mannitol plus dornase alfa changes lung function: FVC mL (percentage change from baseline) compared with dornase alfa (very low certainty).

• Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  231 participants
  Very low

Inhaled tobramycin (TNS) (28 days) vs TNS (56 days)

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 88 participants
  Very low

Inhaled tobramycin (TNS) plus oral azithromycin vs TNS plus oral placebo

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  18 participants
  Low

Ciprofloxacin vs placebo added to cycled and culture‐based inhaled tobramycin (TNS) therapy

The review found no eligible studies for this question.

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: tobramycin for inhalation powder vs tobramycin

The review found no eligible studies for this question.

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found